155 related articles for article (PubMed ID: 36586485)
1. Effect of intravesical mitomycin compared with gemcitabine on the treatment non-muscle invasive bladder cancer: A meta-analysis.
Cheng W; Zhou Y; Chu X; Huang S; Zheng X; Zheng H
Actas Urol Esp (Engl Ed); 2023 Mar; 47(2):92-98. PubMed ID: 36586485
[TBL] [Abstract][Full Text] [Related]
2. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
Li R; Li Y; Song J; Gao K; Chen K; Yang X; Ding Y; Ma X; Wang Y; Li W; Wang Y; Wang Z; Dong Z
BMC Urol; 2020 Jul; 20(1):97. PubMed ID: 32660456
[TBL] [Abstract][Full Text] [Related]
3. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
4. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; Deimling MV; Bianchi A; Pallauf M; Majdoub M; Pradere B; Moschini M; Karakiewicz PI; Teoh JY; Miki J; Kimura T; Shariat SF
Eur Urol Focus; 2023 May; 9(3):463-479. PubMed ID: 36517409
[TBL] [Abstract][Full Text] [Related]
6. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
Cockerill PA; Knoedler JJ; Frank I; Tarrell R; Karnes RJ
BJU Int; 2016 Mar; 117(3):456-62. PubMed ID: 25682834
[TBL] [Abstract][Full Text] [Related]
7. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
[TBL] [Abstract][Full Text] [Related]
8. Thermal intravesical chemotherapy in adjuvant treatment of high risk non-muscle invasive bladder cancer.
Efiloğlu Ö; Bayrak Ö; Turan T; Kazan HÖ; Çulpan M; Çakıcı MÇ; Erturhan S; Yıldırım A
Arch Esp Urol; 2021 Nov; 74(9):875-882. PubMed ID: 34726624
[TBL] [Abstract][Full Text] [Related]
9. Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review.
Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
Investig Clin Urol; 2021 Nov; 62(6):623-630. PubMed ID: 34729962
[TBL] [Abstract][Full Text] [Related]
10. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011935. PubMed ID: 31912907
[TBL] [Abstract][Full Text] [Related]
11. [Intravesical Gemcitabine instillations following BCG failure and allergy to Mitomycin: A unique case of a patient with an inverted papilloma of the bladder].
Matzen M; Offermann A; Tharun L; Perner S; Merseburger AS; Kramer M; Hupe MC
Aktuelle Urol; 2021 Feb; 52(1):43-46. PubMed ID: 33525029
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Cao M; Ma CK; Ma J; Chen HG; Xue W
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):385-7. PubMed ID: 21875472
[TBL] [Abstract][Full Text] [Related]
13. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.
Lightfoot AJ; Breyer BN; Rosevear HM; Erickson BA; Konety BR; O'Donnell MA
Urol Oncol; 2014 Jan; 32(1):35.e15-9. PubMed ID: 23510863
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Zhuo C; Li X; Zhuang H; Tian S; Cui H; Jiang R; Liu C; Tao R; Lin X
Oncotarget; 2016 Dec; 7(50):82567-82579. PubMed ID: 27788495
[TBL] [Abstract][Full Text] [Related]
15. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer.
Breyer BN; Whitson JM; Carroll PR; Konety BR
Urol Oncol; 2010; 28(5):510-4. PubMed ID: 19171491
[TBL] [Abstract][Full Text] [Related]
16. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
[TBL] [Abstract][Full Text] [Related]
17. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gómez Lechuga P; Pareja Vílchez M; Arrabal Martín M
Urol Oncol; 2023 Feb; 41(2):109.e1-109.e8. PubMed ID: 36379812
[TBL] [Abstract][Full Text] [Related]
18. The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer.
Wang L; Huang S; Zhang P; Li H; Li Z; Xue L; Wang Z; Chen Q; Fu D; Luo Q; Li H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8945-8949. PubMed ID: 37160625
[TBL] [Abstract][Full Text] [Related]
19. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
20. The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis.
Zhou W; Liu J; Mao D; Hu C; Gao D
PLoS One; 2022; 17(10):e0276453. PubMed ID: 36269742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
